The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Open accessAbstract
Appropriate cancer care requires a thorough understanding of the natural history of the disease, including the cell of origin, the pattern of clonal evolution, and the functional consequences of the mutations. Using deep sequencing of flow-sorted cell populations from patients with chronic lymphocytic leukemia (CLL), we established the presence of acquired mutations in multipotent hematopoietic progenitors. Mutations affected known lymphoid oncogenes, including BRAF, NOTCH1, and SF3B1. NFKBIE and EGR2 mutations were observed at unexpectedly high frequencies, 10.7% and 8.3% of 168 advanced-stage patients, respectively. EGR2 mutations were associated with a shorter time to treatment and poor overall survival. Analyses of BRAF and EGR2 mutations suggest that they result in deregulation of B-cell receptor (BCR) intracellular signaling. Our data propose disruption of hematopoietic and early B-cell differentiation through the deregulation of pre-BCR signaling as a phenotypic outcome of CLL mutations and show that CLL develops from a pre-leukemic phase. Significance: The origin and pathogenic mechanisms of CLL are not fully understood. The current work indicates that CLL develops from pre-leukemic multipotent hematopoietic progenitors carrying somatic mutations. It advocates for abnormalities in early B-cell differentiation as a phenotypic convergence of the diverse acquired mutations observed in CLL. Cancer Discov; 4(9); 1088–1101. ©2014 AACR. See related commentary by Jiang and Elemento, p. 995 This article is highlighted in the In This Issue feature, p. 973
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Margolin, A. A., Nemenman, I., Basso, K., Wiggins, C., Stolovitzky, G., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-s1-s7 · Cited by 2,420
Margolin, A. A., Nemenman, I. M., Basso, K., Wiggins, C. H., Stolovitzky, G. A., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.7916/d8g15zbp · Cited by 2,246
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029 · cited 1×
“The detection of candidate somatic mutations was performed according to the previously described algorithms with minor modifications (44).”
MethodSelf-citationFrequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramis, G., Jares, P., Beà, S., González-Díaz, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,514
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Wang, L., Lawrence, M. S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner, L., Sivachenko, A., DeLuca, D. S., Zhang, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109016 · Cited by 1,080
Cited by
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Mutations driving CLL and their evolution in progression and relapse
Landau, D. A., Tausch, E., Taylor-Weiner, A. N., Stewart, C., Reiter, J. G., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Böttcher, S., et al. (2015) · Nature · doi:10.1038/nature15395 · Cited by 1,068
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Beà, S., Valdés-Mas, R., Villamor, N., Gutiérrez-Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2015) · Nature · doi:10.1038/nature14666 · Cited by 829
Kipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G., O'Brien, S., Gribben, J., & Rai, K. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.96 · Cited by 517
Paggetti, J., Haderk, F., Seiffert, M., Janji, B., Distler, U., Ammerlaan, W., Kim, Y. J., Adam, J., Lichter, P., Solary, E., et al. (2015) · Blood · doi:10.1182/blood-2014-12-618025 · Cited by 471
Self-citationKwok, B., Hall, J. M., Witte, J. S., Xu, Y., Reddy, P., Lin, K., Flamholz, R., Dabbas, B., Yung, A., Al-Hafidh, J., et al. (2015) · Blood · doi:10.1182/blood-2015-08-667063 · Cited by 317
Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling
Lareau, C. A., Ludwig, L. S., Muus, C., Gohil, S. H., Zhao, T., Chiang, Z., Pelka, K., Verboon, J. M., Luo, W., Christian, E., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-0645-6 · Cited by 315
Oakes, C. C., Seifert, M., Assenov, Y., Gu, L., Przekopowitz, M., Ruppert, A. S., Wang, Q., Imbusch, C. D., Serva, A., Koser, S. D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3488 · Cited by 307
The molecular pathogenesis of chronic lymphocytic leukaemia
Fabbri, G., & Dalla-Favera, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.8 · Cited by 286
Age-related clonal hematopoiesis
Shlush, L. I. (2018) · Blood · doi:10.1182/blood-2017-07-746453 · Cited by 281
Kortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C.-X., Zhu, Y.-X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698092 · Cited by 255
Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation
Frick, M., Chan, W., Arends, C. M., Hablesreiter, R., Halik, A., Heuser, M., Michonneau, D., Blau, O., Hoyer, K., Christen, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2184 · Cited by 223
Self-citationHematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis
Arends, C. M., Galan-Sousa, J., Hoyer, K., Chan, W., Jäger, M., Yoshida, K., Seemann, R., Noerenberg, D., Waldhueter, N., Fleischer-Notter, H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0047-7 · Cited by 194
Self-citationDetection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., & Chaudhuri, A. A. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00390-5 · Cited by 191
Dominguez, P. M., Ghamlouch, H., Rosikiewicz, W., Kumar, P., Béguelin, W., Fontán, L., Rivas, M. A., Pawlikowska, P., Armand, M., Mouly, E., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0657 · Cited by 178
Self-citationFerrando, A. A., & López-Otín, C. (2017) · Nature Medicine · doi:10.1038/nm.4410 · Cited by 120
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation
Yeaton, A., Cayanan, G., Loghavi, S., Dolgalev, I., Leddin, E. M., Loo, C. E., Torabifard, H., Nicolet, D., Wang, J., Corrigan, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1146 · Cited by 94
Identification of cell-type-specific mutations in nodal t-cell lymphomas
Nguyen, T. B., Sakata-Yanagimoto, M., Asabe, Y., Matsubara, D., Kano, J., Yoshida, K., Shiraishi, Y., Chiba, K., Tanaka, H., Miyano, S., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2016.122 · Cited by 93
Self-citationA variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome
Bondu, S., Alary, A.-S., Lefèvre, C., Houy, A., Jung, G., Lefebvre, T., Rombaut, D., Boussaid, I., Bousta, A., Guillonneau, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5467 · Cited by 85
Self-citationB-cell tumor development in tet2-deficient mice
Mouly, E., Ghamlouch, H., Della-Valle, V., Scourzic, L., Quivoron, C., Roos-Weil, D., Pawlikowska, P., Saada, V., Diop, M. K., Lopez, C. K., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017014118 · Cited by 58
Self-citationRoos-Weil, D., Decaudin, C., Armand, M., Della-Valle, V., Diop, M. K., Ghamlouch, H., Ropars, V., Hérate, C., Lara, D., Durot, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0873 · Cited by 38
Self-citationPreleukemia: the normal side of cancer
Shlush, L. I., & Minden, M. D. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000111 · Cited by 23
Metadata
- Authors
- Damm, F., Mylonas, E., Cosson, A., Yoshida, K., Della Valle, V., Mouly, E., Diop, M., Scourzic, L., Shiraishi, Y., Chiba, K., Tanaka, H., Miyano, S., Kikushige, Y., Davi, F., Lambert, J., Gautheret, D., Merle-Béral, H., Sutton, L., Dessen, P., Solary, E., Akashi, K., Vainchenker, W., Mercher, T., Droin, N., Ogawa, S., Nguyen-Khac, F., & Bernard, O. A.
- Venue
- Cancer Discovery
- Published
- 2014-09-01
- Volume
- 4
- Issue
- 9
- Pages
- 1088-1101
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2148576269
- Cited by
- 267
- References
- 48
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.